Daniela De Zio

13PUBLICATIONS
53CO-AUTHORS
Solid tumoursMolecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Aug 26, 2026
A Phase Ib/II Study of Atezolizumab in Combination with Thiopurine Therapy in Patients with Metastatic Solid Tumors and Intermediate Tumor Mutational Burden.

|Feb 24, 2025
Thiopurine therapy enhances immune checkpoint inhibitor efficacy in low-mutational burden melanoma: A promising anticancer approach.

Loulieta Nazerai, Christina Tsiavou, Lina Vardouli

|Jun 13, 2024
AMBRA1 levels predict resistance to MAPK inhibitors in melanoma.

Luca Di Leo, Chiara Pagliuca, Ali Kishk

|Jan 27, 2024
An analysis pipeline for understanding 6-thioguanine effects on a mouse tumour genome.

Patricio Yankilevich, Loulieta Nazerai, Shona Caroline Willis

|Jul 26, 2023
Metabolic modelling-based in silico drug target prediction identifies six novel repurposable drugs for melanoma.

Tamara Bintener, Maria Pires Pacheco, Demetra Philippidou

|Mar 03, 2023
Ambra1 modulates the tumor immune microenvironment and response to PD-1 blockade in melanoma.

Alex Frias, Luca Di Leo, Asier Antoranz

Pageof 3

Frequent Collaborators

7 joint publications

Luca Di Leo

3 joint publications

Loulieta Nazerai

3 joint publications

Salvatore Rizza

3 joint publications

Francesco Cecconi